For an adult with idiopathic pulmonary fibrosis, how do nerandomilast (brand Jascayd) and nintedanib (brand Ofev) compare regarding dosing, efficacy, side effects, contraindications, and monitoring?

Nerandomilast vs Nintedanib (Ofev) for Idiopathic Pulmonary Fibrosis

For adults with IPF, nerandomilast (Jascayd) offers comparable efficacy to nintedanib (Ofev) in slowing FVC decline but with substantially better gastrointestinal tolerability, making it the preferred first-line antifibrotic agent when tolerability is a concern. 1

Dosing

Nerandomilast:

• Standard dose: 18 mg twice daily (approximately 12 hours apart)
• Reduced dose: 9 mg twice daily (only for intolerance, NOT when combined with pirfenidone)
• Can be taken with or without food
• Tablets may be swallowed whole or dispersed in water 2

Nintedanib (Ofev):

• Standard dose: 150 mg twice daily
• Reduced dose: 100 mg twice daily (for tolerability issues)
• Should be taken with food to improve GI tolerability 3

Key dosing consideration: When combining nerandomilast with strong CYP3A inhibitors, reduce to 9 mg twice daily. No such interaction concerns exist for nintedanib 2.

Efficacy Comparison

Both agents demonstrate similar efficacy in reducing FVC decline:

Nerandomilast (FIBRONEER-IPF trial):

• Reduced FVC decline by 68.8 ml/year compared to placebo (18 mg dose)
• Adjusted annual FVC change: -114.7 ml vs -183.5 ml with placebo (P<0.001)
• 77.7% of patients were on background antifibrotic therapy (nintedanib or pirfenidone) 1

Nintedanib (INPULSIS trials):

• Reduced FVC decline by 125.3 ml/year (INPULSIS-1) and 93.7 ml/year (INPULSIS-2) compared to placebo
• Adjusted annual FVC change: approximately -114 ml vs -207-240 ml with placebo 4

The efficacy profiles are essentially equivalent—both slow disease progression by approximately 50% compared to placebo 5. Neither drug reverses established fibrosis; both provide disease stabilization 6.

Side Effects Profile

This is where the drugs diverge significantly:

Nerandomilast:

• Diarrhea: 41.3% (18 mg dose) vs 16.0% placebo
• Generally mild GI symptoms
• Discontinuation due to adverse events: ~12% 1, 7
• Nausea and fatigue reported but less severe than nintedanib 8

Nintedanib:

• Diarrhea: 61.5-63.2% vs 18.3-18.6% placebo
• Abdominal pain: 4.2× higher than placebo
• Nausea: 3.1× higher
• Vomiting: 3.6× higher
• Weight loss: 3.7× higher
• Elevated liver enzymes (AST/ALT): 3.2-3.6× higher
• Dose reduction required: 7.9× more likely
• Discontinuation: 1.9× more likely 9

Critical distinction: Nerandomilast demonstrates the best tolerability and safety profile among all three available antifibrotics (including pirfenidone) 5. The GI side effects are substantially less severe and less frequent than nintedanib.

Contraindications

Nerandomilast: None listed 2

Nintedanib:

• Pregnancy (teratogenic)
• Severe hepatic impairment
• Caution with bleeding risk (anticoagulant properties) 3

Monitoring Requirements

Both agents require similar monitoring per ATS/ERS/JRS/ALAT guidelines:

• Pulmonary function testing and 6-minute walk test: Every 4-6 months or sooner if clinically indicated
• Annual HRCT: If clinical suspicion of worsening or lung cancer risk
• Liver function tests: Baseline and periodic monitoring (especially critical for nintedanib given 3.2-3.6× elevation risk)
• Evaluate for lung transplantation: At diagnosis if increased mortality risk 9

Nintedanib-specific monitoring:

• More frequent LFT monitoring due to higher hepatotoxicity risk
• Monitor for bleeding complications
• Weight monitoring due to significant weight loss risk 9

Clinical Decision Algorithm

Choose Nerandomilast when:

• Starting antifibrotic therapy in treatment-naïve patients
• Patient has GI comorbidities or concerns about tolerability
• Patient is on anticoagulation (nintedanib has bleeding risk)
• Patient has borderline liver function
• Considering combination with pirfenidone (nerandomilast maintains 18 mg dose) 2

Choose Nintedanib when:

• Patient has systemic sclerosis-associated ILD (nintedanib has this specific indication) 3
• Nerandomilast is unavailable or not covered by insurance
• Patient has already tolerated nintedanib well

Combination therapy: Nerandomilast can be combined with pirfenidone or nintedanib. The FIBRONEER trials showed efficacy both as monotherapy and with background antifibrotic therapy 1, 7.

Mortality Data

Nerandomilast demonstrated a significant mortality benefit in the FIBRONEER-ILD trial extension:

• Hazard ratio for death: 0.51 (95% CI 0.34-0.78) for both doses vs placebo
• This represents a 49% reduction in mortality risk 7

Nintedanib: No significant mortality benefit demonstrated in primary trials, though this was not a primary endpoint 4.

Bottom Line

Nerandomilast represents a mechanistically distinct therapeutic option (PDE4B inhibitor vs tyrosine kinase inhibitor) with equivalent efficacy but superior tolerability compared to nintedanib 5, 6. The substantially lower GI adverse event burden (41% vs 62% diarrhea rate) and lower discontinuation rates make nerandomilast the preferred initial choice for most patients with IPF. The emerging mortality benefit data further supports this preference 7. However, nintedanib remains valuable for patients with SSc-ILD and those already tolerating it well 3.